Show simple item record

dc.contributor.authorAntunes, Dinler A.
dc.contributor.authorRigo, Mauricio M.
dc.contributor.authorFreitas, Martiela V.
dc.contributor.authorMendes, Marcus F. A.
dc.contributor.authorSinigaglia, Marialva
dc.contributor.authorLizee, Gregory
dc.contributor.authorKavraki, Lydia E.
dc.contributor.authorSelin, Liisa K.
dc.contributor.authorCornberg, Markus
dc.contributor.authorVieira, Gustavo F.
dc.date2022-08-11T08:09:49.000
dc.date.accessioned2022-08-23T16:44:23Z
dc.date.available2022-08-23T16:44:23Z
dc.date.issued2017-10-04
dc.date.submitted2018-03-14
dc.identifier.citation<p>Front Immunol. 2017 Oct 4;8:1210. doi: 10.3389/fimmu.2017.01210. eCollection 2017. <a href="https://doi.org/10.3389/fimmu.2017.01210">Link to article on publisher's site</a></p>
dc.identifier.issn1664-3224 (Linking)
dc.identifier.doi10.3389/fimmu.2017.01210
dc.identifier.pmid29046675
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40489
dc.description.abstractImmunotherapy has become one of the most promising avenues for cancer treatment, making use of the patient's own immune system to eliminate cancer cells. Clinical trials with T-cell-based immunotherapies have shown dramatic tumor regressions, being effective in multiple cancer types and for many different patients. Unfortunately, this progress was tempered by reports of serious (even fatal) side effects. Such therapies rely on the use of cytotoxic T-cell lymphocytes, an essential part of the adaptive immune system. Cytotoxic T-cells are regularly involved in surveillance and are capable of both eliminating diseased cells and generating protective immunological memory. The specificity of a given T-cell is determined through the structural interaction between the T-cell receptor (TCR) and a peptide-loaded major histocompatibility complex (MHC); i.e., an intracellular peptide-ligand displayed at the cell surface by an MHC molecule. However, a given TCR can recognize different peptide-MHC (pMHC) complexes, which can sometimes trigger an unwanted response that is referred to as T-cell cross-reactivity. This has become a major safety issue in TCR-based immunotherapies, following reports of melanoma-specific T-cells causing cytotoxic damage to healthy tissues (e.g., heart and nervous system). T-cell cross-reactivity has been extensively studied in the context of viral immunology and tissue transplantation. Growing evidence suggests that it is largely driven by structural similarities of seemingly unrelated pMHC complexes. Here, we review recent reports about the existence of pMHC "hot-spots" for cross-reactivity and propose the existence of a TCR interaction profile (i.e., a refinement of a more general TCR footprint in which some amino acid residues are more important than others in triggering T-cell cross-reactivity). We also make use of available structural data and pMHC models to interpret previously reported cross-reactivity patterns among virus-derived peptides. Our study provides further evidence that structural analyses of pMHC complexes can be used to assess the intrinsic likelihood of cross-reactivity among peptide-targets. Furthermore, we hypothesize that some apparent inconsistencies in reported cross-reactivities, such as a preferential directionality, might also be driven by particular structural features of the targeted pMHC complex. Finally, we explain why TCR-based immunotherapy provides a special context in which meaningful T-cell cross-reactivity predictions can be made.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29046675&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright: © 2017 Antunes, Rigo, Freitas, Mendes, Sinigaglia, Lizée, Kavraki, Selin, Cornberg and Vieira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectT-cell cross-reactivity
dc.subjectTCR-interacting surface
dc.subjectTCR/pMHC
dc.subjectcancer immunotherapy
dc.subjectcross-reactivity hot-spots
dc.subjecthierarchical clustering
dc.subjectpeptide–MHC complex
dc.subjectImmunopathology
dc.subjectImmunoprophylaxis and Therapy
dc.subjectNeoplasms
dc.subjectTherapeutics
dc.titleInterpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy
dc.typeJournal Article
dc.source.journaltitleFrontiers in immunology
dc.source.volume8
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4305&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3294
dc.identifier.contextkey11771540
refterms.dateFOA2022-08-23T16:44:23Z
html.description.abstract<p>Immunotherapy has become one of the most promising avenues for cancer treatment, making use of the patient's own immune system to eliminate cancer cells. Clinical trials with T-cell-based immunotherapies have shown dramatic tumor regressions, being effective in multiple cancer types and for many different patients. Unfortunately, this progress was tempered by reports of serious (even fatal) side effects. Such therapies rely on the use of cytotoxic T-cell lymphocytes, an essential part of the adaptive immune system. Cytotoxic T-cells are regularly involved in surveillance and are capable of both eliminating diseased cells and generating protective immunological memory. The specificity of a given T-cell is determined through the structural interaction between the T-cell receptor (TCR) and a peptide-loaded major histocompatibility complex (MHC); i.e., an intracellular peptide-ligand displayed at the cell surface by an MHC molecule. However, a given TCR can recognize different peptide-MHC (pMHC) complexes, which can sometimes trigger an unwanted response that is referred to as T-cell cross-reactivity. This has become a major safety issue in TCR-based immunotherapies, following reports of melanoma-specific T-cells causing cytotoxic damage to healthy tissues (e.g., heart and nervous system). T-cell cross-reactivity has been extensively studied in the context of viral immunology and tissue transplantation. Growing evidence suggests that it is largely driven by structural similarities of seemingly unrelated pMHC complexes. Here, we review recent reports about the existence of pMHC "hot-spots" for cross-reactivity and propose the existence of a TCR interaction profile (i.e., a refinement of a more general TCR footprint in which some amino acid residues are more important than others in triggering T-cell cross-reactivity). We also make use of available structural data and pMHC models to interpret previously reported cross-reactivity patterns among virus-derived peptides. Our study provides further evidence that structural analyses of pMHC complexes can be used to assess the intrinsic likelihood of cross-reactivity among peptide-targets. Furthermore, we hypothesize that some apparent inconsistencies in reported cross-reactivities, such as a preferential directionality, might also be driven by particular structural features of the targeted pMHC complex. Finally, we explain why TCR-based immunotherapy provides a special context in which meaningful T-cell cross-reactivity predictions can be made.</p>
dc.identifier.submissionpathoapubs/3294
dc.contributor.departmentSelin Lab, Department of Pathology
dc.source.pages1210


Files in this item

Thumbnail
Name:
fimmu_08_01210.pdf
Size:
9.050Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright: © 2017 Antunes, Rigo, Freitas, Mendes, Sinigaglia, Lizée, Kavraki, Selin, Cornberg and Vieira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as Copyright: © 2017 Antunes, Rigo, Freitas, Mendes, Sinigaglia, Lizée, Kavraki, Selin, Cornberg and Vieira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.